Catalent Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>CA</div>
CTLT -- USA Stock  

USD 84.23  0.06  0.07%

Catalent is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 31st of August 2020. While many of us are getting excited about healthcare space, we are going to review the feasibility of acquiring Catalent. Should we be more optimistic in anticipation of a recovery?
Published over two weeks ago
View all stories for Catalent | View All Stories
Our newest take on Catalent (NYSE:CTLT) analyst consensus
Catalent is OVERVALUED at 76.35 per share with modest projections ahead. Macroaxis provides advice on Catalent to complement and cross-verify current analyst consensus on Catalent. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon.
What is the right price you would pay to acquire a share of Catalent? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Catalent this year

Annual and quarterly reports issued by Catalent are formal financial statements that are published yearly and quarterly and sent to Catalent stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Catalent often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Catalent utilizes its cash?

To perform a cash flow analysis of Catalent, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Catalent is receiving and how much cash it distributes out in a given period. The Catalent cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Catalent Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Catalent reported Net Cash Flow from Operations of 440.3 Million in 2019

An Additional Perspective On Catalent

Earning per share calculations of Catalent is based on official Zacks consensus of 4 analysts regarding Catalent's future annual earnings. Given the historical accuracy of 87.49%, the future earnings per share of the company is estimated to be 1.8225 with the lowest and highest values of 1.77 and 1.89, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.

Is Catalent a risky opportunity?

Let's check the volatility. Catalent is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Catalent (NYSE:CTLT) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of a Catalent stock makes you a part-owner of that company.

Catalent Current Consensus

Here is the newest trade recommendation based on an ongoing consensus estimate among financial analysis covering Catalent. The Catalent consensus assessment is calculated by taking the average estimates from all of the analysts covering Catalent

Strong Buy
Strong Buy866.67
Strong Sell00.0

Catalent will most likely finish below $89 in 60 days

Newest Information Ratio is up to 0.02. Price may drop again. Catalent currently demonstrates below-verage downside deviation. It has Information Ratio of 0.02 and Jensen Alpha of 0.18. However, we do advice investors to further question Catalent expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Final Take On Catalent

Whereas few other entities in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Catalent may not be as strong as the others in terms of longer-term growth potentials. On the whole, as of the 30th of August 2020, our up-to-date 30 days 'Buy-vs-Sell' recommendation on the firm is Hold. We believe Catalent is overvalued with below average odds of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Catalent. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to